Life insurance carriers are increasingly turning to accelerated underwriting (AUW) to improve the applicant experience, shorten cycle times, and reduce underwriting expense. By waiving traditional underwriting requirements for applicants who appear to meet favorable risk criteria, AUW can create operational and commercial value. However, bypassing traditional evidences, such as labs and exams, can lead to different assessments of the same risks, often resulting in mortality slippage from reduced underwriting rigor.
This paper asserts that mortality slippage should not be assessed with a single universal metric. Instead, the appropriate measurement depends on the business objective or realized outcome of the AUW program.
When AUW is intended to increase sales, percentage mortality slippage relative to fully underwritten (FUW) expected mortality is often the more relevant measure because slippage functions similar to a sales promotion economically. When AUW is intended to reduce underwriting cost without increasing sales volume, incremental present value of death benefits (PVDB) is the more appropriate measure because it directly compares dollar savings from underwriting expense reductions with dollar losses from mortality risk.
AUW has become an important feature of the individual life insurance market. AUW is commonly defined as the waiver of traditional requirements, such as fluids or paramedical examinations, for a subset of applicants within an otherwise fully underwritten process. Because many AUW programs are relatively young and credible claims experience is still emerging, carriers often rely on monitoring methods such as random holdouts and post-issue audits to estimate the extent of underwriting misclassification and resulting mortality slippage.
The central challenge is not whether mortality slippage exists. Some level of slippage is expected whenever evidence requirements are reduced. The more important question is whether the slippage is economically acceptable in relation to the purpose of the AUW program. A program designed primarily to generate additional sales should be evaluated differently than a program designed primarily to reduce underwriting cost on business that would have been sold anyway. These two objectives create different economic tradeoffs; therefore, they require different slippage metrics.
The first approach measures mortality slippage as a percentage of FUW expected mortality. A 10% slippage estimate means that mortality for the AUW-issued block is expected to be 10% higher than it would have been under FUW. This measure is intuitive, comparable across programs, and useful for communicating the overall relative mortality impact of underwriting acceleration.
However, a percentage measure is inherently relative. It does not fully reflect the absolute dollar amount of mortality risk created by a misclassification. A 10% deterioration in mortality for a young applicant with a modest face amount will have a smaller economic impact than a 10% deterioration for an older applicant with an otherwise similar risk profile and a larger face amount.
The second approach measures mortality slippage as the incremental present value of death benefits (PVDB) caused by underwriting misclassification. PVDB is an actuarial measure of mortality. It is a present value of expected future death claims. Under this framework, each misclassified case is assigned an incremental dollar cost equal to the additional expected death benefit attributable to the AUW decision relative to the FUW decision.
For example, a 35-year-old male who does not use tobacco applies for a $250,000, 20-year term policy. An AUW process classifies him as super preferred non-tobacco, while FUW would have classified the same applicant as standard non-tobacco. If that misclassification creates an additional $69 of PVDB, then the economic cost of the AUW misclassification for that case is $69 of present value. The same calculation can be performed for each audited or monitored case and averaged across a segment, cohort, distribution channel, or overall AUW program.
Unlike percentage slippage, incremental PVDB reflects the absolute risk load associated with age, sex, tobacco status, face amount, product type, and policy duration. This distinction is critical because insurance premiums are fundamentally tied to absolute expected mortality.
The primary difference between the two approaches lies in their focus – percentage slippage quantifies relative mortality deterioration, while PVDB captures the absolute economic impact. Percentage slippage can be expressed either as a percentage of mortality or as a percentage of PVDB, providing insight into how much higher AUW mortality is compared to FUW mortality on a relative scale. In contrast, PVDB addresses a separate question by quantifying the additional claim costs expected due to AUW misclassification.
Both are useful, but not interchangeable. A program may show acceptable percentage slippage yet still generate unacceptable dollar losses if the slippage is concentrated among older ages, larger face amounts, longer benefit durations, or other segments with high absolute mortality exposure. Conversely, a noticeable percentage deterioration in a low-risk segment may have only a modest dollar impact.
When the business objective of AUW is to increase sales, percentage mortality slippage is generally the more appropriate primary measure. In this context, mortality slippage can be understood as a cost of sales promotion: The carrier accepts some additional mortality risk in exchange for a faster, easier, and less intrusive buying process that may improve placement rates, increase sales volume, or reduce applicant drop-off.
Although slippage may be more costly in absolute dollars for older ages, higher face amounts, and longer coverage durations, the additional sales generated by the AUW program may also produce proportionally higher premium income. Therefore, the key economic test is not whether AUW eliminates slippage, but whether the incremental premium and business value from increased sales are sufficient to offset the expected deterioration in mortality.
Under this scenario, an AUW program is successful when the value of additional sales more than compensates for the associated mortality slippage. Percentage slippage is useful because it expresses the relative mortality cost of acceleration and can be compared with expected growth in volume, premium, and contribution margin. However, this cost-benefit tradeoff is valid only if mortality slippage remains low enough for the overall business to remain profitable; otherwise, increasing sales of unprofitable business would create additional economic loss.
When the business objective of AUW is to reduce underwriting costs without increasing sales volume, incremental PVDB is the more appropriate primary measure. In this scenario, the carrier is not receiving a meaningful offset from additional premium volume. The economic benefit is the reduction in underwriting expense, such as fewer medical exams, fewer laboratory tests, fewer attending physician statements, and shorter manual review time.
This evaluation is conceptually similar to a protective value study. The carrier compares dollars saved from reduced underwriting requirements with dollars lost from additional expected mortality. Because there is no proportional sales increase to offset the mortality cost, the absolute dollar value of slippage becomes central to the analysis.
A misclassification involving an older applicant or a large face amount may be far more costly than a similar relative misclassification involving a younger applicant or a smaller policy. PVDB captures this difference directly. For this objective, a successful AUW program creates underwriting cost savings greater than the incremental PVDB cost of mortality slippage.
Carriers should avoid relying on a single slippage metric without first clarifying the purpose of the AUW program. If AUW is expected to increase sales, monitoring should connect percentage mortality slippage to incremental premium, placement rates, distribution channel performance, and contribution margin. If AUW is expected to reduce underwriting expense, monitoring should emphasize incremental PVDB and compare it directly with underwriting cost savings.
In practice, both measures can be valuable. Percentage slippage provides a high-level view of relative underwriting effectiveness, while PVDB provides a financial view of the economic cost of misclassification. A robust monitoring framework should track both, but the primary decision metric should align with the carrier’s business objective.
Segmentation is also important. AUW slippage should be analyzed by:
This segmentation can help carriers identify where AUW creates the most value, where it creates the most risk, and where eligibility rules or evidence requirements should be adjusted.
Mortality slippage is an unavoidable consideration in accelerated underwriting, but it should not be interpreted in isolation. The appropriate measure depends on the purpose of the AUW program.
A clear understanding of business objectives can help carriers assess the true cost effectiveness of AUW programs, set appropriate monitoring standards, and make better decisions regarding eligibility rules, evidence requirements, and program expansion. Ultimately, mortality slippage should be measured not only as an underwriting outcome, but also as an economic tradeoff tied to the strategic objective of the AUW program.
Contact us to further the discussion about assessing the cost effectiveness of accelerated underwriting programs.
